These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 25514914)

  • 1. Phytotherapy and NAFLD--from goals and challenges to clinical practice.
    Milosević N; Milanović M; Abenavoli L; Milić N
    Rev Recent Clin Trials; 2014; 9(3):195-203. PubMed ID: 25514914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo efficacy study of milk thistle extract (ETHIS-094™) in STAM™ model of nonalcoholic steatohepatitis.
    Pais P; D'Amato M
    Drugs R D; 2014 Dec; 14(4):291-9. PubMed ID: 25404123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New therapeutic potentials of milk thistle (Silybum marianum).
    Milić N; Milosević N; Suvajdzić L; Zarkov M; Abenavoli L
    Nat Prod Commun; 2013 Dec; 8(12):1801-10. PubMed ID: 24555302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis.
    Wah Kheong C; Nik Mustapha NR; Mahadeva S
    Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1940-1949.e8. PubMed ID: 28419855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Milk thistle in liver diseases: past, present, future.
    Abenavoli L; Capasso R; Milic N; Capasso F
    Phytother Res; 2010 Oct; 24(10):1423-32. PubMed ID: 20564545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Milk thistle (Silybum marianum) for the therapy of liver disease.
    Flora K; Hahn M; Rosen H; Benner K
    Am J Gastroenterol; 1998 Feb; 93(2):139-43. PubMed ID: 9468229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silymarin: not just another antioxidant.
    Camini FC; Costa DC
    J Basic Clin Physiol Pharmacol; 2020 Mar; 31(4):. PubMed ID: 32134732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Milk thistle: is there a role for its use as an adjunct therapy in patients with cancer?
    Ladas EJ; Kelly KM
    J Altern Complement Med; 2003 Jun; 9(3):411-6. PubMed ID: 12816629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
    Faghihzadeh F; Adibi P; Hekmatdoost A
    Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Milk thistle to treat non-alcoholic fatty liver disease: dream or reality?
    Abenavoli L; Bellentani S
    Expert Rev Gastroenterol Hepatol; 2013 Nov; 7(8):677-9. PubMed ID: 24134155
    [No Abstract]   [Full Text] [Related]  

  • 11. Milk thistle and its derivative compounds: a review of opportunities for treatment of liver disease.
    Hackett ES; Twedt DC; Gustafson DL
    J Vet Intern Med; 2013; 27(1):10-6. PubMed ID: 23140176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silybum marianum (milk thistle) and its main constituent, silymarin, as a potential therapeutic plant in metabolic syndrome: A review.
    Tajmohammadi A; Razavi BM; Hosseinzadeh H
    Phytother Res; 2018 Oct; 32(10):1933-1949. PubMed ID: 30015401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herbal medicines for liver diseases.
    Dhiman RK; Chawla YK
    Dig Dis Sci; 2005 Oct; 50(10):1807-12. PubMed ID: 16187178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.
    Faghihzadeh F; Adibi P; Rafiei R; Hekmatdoost A
    Nutr Res; 2014 Oct; 34(10):837-43. PubMed ID: 25311610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum [L.] Gaertn.).
    Tamayo C; Diamond S
    Integr Cancer Ther; 2007 Jun; 6(2):146-57. PubMed ID: 17548793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of plants used in the treatment of liver disease: part 1.
    Luper S
    Altern Med Rev; 1998 Dec; 3(6):410-21. PubMed ID: 9855566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of plants used in the treatment of liver disease: part two.
    Luper S
    Altern Med Rev; 1999 Jun; 4(3):178-88. PubMed ID: 10383482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of silymarin in patients with non-alcoholic fatty liver disease - the Siliver trial: a study protocol for a randomized controlled clinical trial.
    de Avelar CR; Nunes BVC; da Silva Sassaki B; Dos Santos Vasconcelos M; de Oliveira LPM; Lyra AC; Bueno AA; de Jesus RP
    Trials; 2023 Mar; 24(1):177. PubMed ID: 36899430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herbal medicines and nonalcoholic fatty liver disease.
    Yao H; Qiao YJ; Zhao YL; Tao XF; Xu LN; Yin LH; Qi Y; Peng JY
    World J Gastroenterol; 2016 Aug; 22(30):6890-905. PubMed ID: 27570425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The therapeutic effect of silymarin in the treatment of nonalcoholic fatty disease: A meta-analysis (PRISMA) of randomized control trials.
    Zhong S; Fan Y; Yan Q; Fan X; Wu B; Han Y; Zhang Y; Chen Y; Zhang H; Niu J
    Medicine (Baltimore); 2017 Dec; 96(49):e9061. PubMed ID: 29245314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.